A comment on the article: Stošić S, Karanović N. Health care economics in Serbia: Current problems and changes. Vojnosanit Pregl 2014; 71(11): 1055–1061;Komentar članka: Stošić S, Karanović N. Ekonomija zdravstvenog sistema Srbije: Tekući problem i promene. Vojnosanit Pregl 2014; 71(11): 1055–1061

Vojnosanitetski Pregled

Volumn 72, Issue 2, 2015, Pages 203-205

  Jakovljević, Mihajlo B ^a  

^a UNIVERSITY OF KRAGUJEVAC   (Serbia)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG;

COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; FUNDING; HEALTH CARE COST; HEALTH CARE FINANCING; HEALTH CARE PLANNING; HEALTH CARE SYSTEM; HUMAN; LETTER; MEDICAL EDUCATION; MEDICAL TECHNOLOGY; PHARMACOECONOMICS; PUBLIC HEALTH SERVICE; SERBIA; ECONOMICS; HEALTH CARE DELIVERY; STATISTICAL MODEL;

DELIVERY OF HEALTH CARE; HUMANS; MODELS, ECONOMIC;

EID: 84923221023     PISSN: 00428450     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (26)

1. Stošić S, Karanović N. Health care economics in Serbia: Current problems and changes. Vojnosanit Pregl 2014; 71(11): 1055–61. (Serbian).
2. Jakovljević M, Jovanović M, Lazić Z, Jakovljević V, Đukić A, Velicković R, et al. Current efforts and proposals to reduce healthcare costs in Serbia. SJECR 2011; 12(4): 161–3.
3. Jakovljevic M, Varjacic M, Jankovic SM. Cost-Effectiveness of Ritodrine and Fenoterol for Treatment of Preterm Labor in a Low–Middle-Income Country: A Case Study. Value Health 2008; 11(2): 149–53.
4. Jovanovic M, Jakovljevic M. Inpatient detoxification procedure and facilities: financing considerations from an Eastern European perspective. Alcohol Alcoholism 2011; 46(3): 364–5.
5. Jakovljevic MB, Jovanovic M, Nikic K, Dejanovic SD, Radovanovic A, Pirkovic I, et al. Acute Alcohol Detoxification Costs in Upper-Middle Income: Western Balkans. J Health Behav Pub Health 2011; 1(2): 1–7.
6. Jakovljević M, Jovanović M. Current state and the costs of opioid dependence treatment in the Serbian health sector 2011; 43(2): 197–9. (Serbian).
7. Biorac N, Jakovljević MB, Stefanović D, Perović S, Janković, S. Assessment of diabetes mellitus type 2 treatment costs in the Republic of Serbia. Vojnosanit Pregl 2009; 66(4): 271–6. (Serbian).
8. Jakovljevic M, Cupurdija V, Lazic Z. Cost of illness of communityacquired pneumonia. Review of the literature and possible strategies in the Serbian health care setting. Farmeconomia. Health economics and therapeutic pathways 2013; 14(4): 133–9.
9. Radovanović A, Dagović A, Jakovljević, M. Economics of cancer related medical care: worldwide estimates and available domestic evidence. Archive of Oncology 2011; 19(3-4): 59–63.
10. Jakovljevic MB, Lazic Z, Gajovic O, Tanaskovic I, Milovanovic D, Atanasijevic D. GOLD Stage Impact on COPD Direct Medical Costs in Elderly. J Health Behav Pub Health 2012; 2(3): 1–7. (Serbian).
11. Jakovljevic M, Mijailovic Z, Jovicic BP, Canovic P, Gajovic O, Jovanovic M, et al. Assessment of Viral Genotype Impact to the Cost-Effectiveness and Overall Costs of Care for Peg-Interferon-2α+ Ribavirine Treated Chronic Hepatitis C Patients. Hepat Mon 2013 13(6): e6750. (Serbian).
12. Jakovljevic M, Zugic A, Rankovic A, Dagovic A. Radiation therapy remains the key cost driver of oncology inpatient treatment. J Med Econ 2015; 18(1): 29–36.
13. Jakovljevic M, Gutzwiller F, Schwenkglenks M, Milovanovic O, Rancic N, Varjacic M, et al. Costs differences among monoclonal antibodies-based first-line oncology cancer protocols for breast cancer, colorectal carcinoma and non-Hodgkin’s lymphoma. JBUON 2014; 19(3): 1111–20.
14. Rankovic A, Rancic N, Jovanovic M, Ivanovic M, Gajovic O, Lazic Z, et al. Impact of imaging diagnostics on the budget – Are we spending too much? Vojnosanit Pregl 2013; 70(7): 709–11. (Serbian).
15. Jakovljevic MB. Resource allocation strategies in Southeastern European health policy. Eur J Health Econ 2013; 14(2): 153–9.
16. Jakovljevic M, Jovanovic M, Rancic N, Vyssoki B, Djordjevic N. LAT Software Induced Savings on Medical Costs of Alcohol Addicts' Care-Results from a Matched-Pairs Case-Control Study. PLoS One 2014; 9(11): e111931.
17. Jakovljevic MB, Nakazono S, Ogura S. Contemporary generic market in Japan-key conditions to successful evolution. Expert Rev Pharmacoecon Outcomes Res 2014; 14(2): 181–94.
18. Suhrcke M, Rocco L, McKee M. Health: a vital investment for economic development in Eastern Europe and central Asia. Copenhagen; European Observatory on Health Systems and Policies, 2007.
19. Obradović M. Prof., Dr. Mihajlo Jakovljević: Health economics with pharmacoeconomics, University of Kragujevac, Faculty of Medicine sciences, Kragujevac, 2014. Vojnosanit Pregl 2014; 71(11): 1085–1085. (Serbian).
20. Gulácsi L, Orlewska E, Péntek M. Health economics and health technology assessment in Central and Eastern Europe: a dose of reality. Eur J Health Econ 2012; 13(5): 525–31.
21. Sorenson C, Kanavos P, Karamalis M. HTA in central and Eastern Europe: current status, challenges and opportunities. JMDR 2009; 6(1): 34–45.
22. Bredencamp C, Gragnolati M. Financing in the Western Balkans: An Overview of Progress and Challenges. South East Europe Review 2008; 11(2): 151–84.
23. The World Bank. World Bank Database; Country and Lending Groups. Available from: http://data.worldbank.org/about/country-and-lendinggroups#High_income [accessed 2014 November 24].
24. Jakovljevic MB. The Key Role of the Leading Emerging BRIC Markets in the Future of Global Health Care. SJECR 2014; 15(3): 139–43.
25. World Health Organization. European Health for All HFA-DB database. Available from: http://data.euro.who.int/hfadb [accessed 2014 November 24].
26. Jakovljevic MB. Health Expenditure Dynamics in Serbia 1995–2012. Hospital Pharmacology 2014; 1(3): 180–3.